<DOC>
	<DOCNO>NCT00529750</DOCNO>
	<brief_summary>Primary : - To evaluate impact irbesartan endothelial function hypertensive patient metabolic syndrome . Secondary : - To evaluate oxidative stress status patient hypertension metabolic syndrome . - To correlate oxidative stress status endothelial function patient . - To evaluate effect irbesartan oxidative stress stage patient metabolic syndrome correlate effect endothelial function . - To correlate change endothelial function oxidative stress stage change arterial pressure level .</brief_summary>
	<brief_title>Effect Angiotensin II Receptor Antagonist Irbesartan Biochemical Functional Markers Endothelial Dysfunction Patients With Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<criteria>Hypertension grade 1 2 With least two follow criterion diagnosis metabolic syndrome : Body mass index &gt; = 25 kg/m2 AND waist circumference &gt; = 100 cm . Dyslipidemia ( triglyceride fast serum level &gt; = 200 mg/dL OR HDL serum level &lt; = 40 mg/dL ) Fasting serum glucose &gt; = 110 mg/dL &lt; 126 mg/dL Known hypersensitivity Irbesartan Hypertension grade 3 History clinical vascular event TIAs , stroke , peripheral arterial disease Coronary artery disease Renal insufficiency ( creatinine serum level &gt; = 1.2 mg/dL ) Presence clinical heart failure Asthma COPD Valvular cardiopathy clinically relevant Current therapy antioxidant drug , statin Therapy AIIRA least 3 month last semester Presence acute illness major trauma last 8 week History chronic inflammatory disease rheumatoid arthritis , immune disorder connective tissue disease . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>